- ►eastarnet.com [PDF] N Hotta, T Toyota, K Matsuoka, Y Shigeta, R … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—Over the course of the study, five of the eight electrophysiological
measures assessed showed significant improvement from baseline in the
fidarestat-treated group, whereas no measure showed significant ... Cited by 15 - Related articles - All 4 versions
- Free from Publisher N Hotta, T Toyota, K Matsuoka, Y Shigeta, R … - Diabetes Care, 2001 - cat.inist.fr OBJECTIVE The purpose of this study was to evaluate the efficacy of fidarestat,
a novel aldose reductase BAR) inhibitor, in a double-blind placebo controlled
study in patients with type 1 and type 2 diabetes and associated peripheral ... Cited by 63 - Related articles - BL Direct - All 5 versions
M Kihara, Y Mitsui, M Shioyama, T Hasegawa … - Neuroscience letters, 2001 - Elsevier The effects of zenarestat, an aldose reductase inhibitor, on endoneurial blood
flow (NBF) were explored in streptozotocin-induced diabetic rats. Rats were
maintained on a diet of containing 0.09% zenarestat for 8 weeks, then NBF ... Cited by 7 - Related articles - All 4 versions
M Oka, Y Matsumoto, S Sugiyama, N Tsuruta … - J. Med. Chem, 2000 - pubs.acs.org The absolute configuration of the aldose reductase (AR) inhibitor, (+)-(2S,4S)-6
-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (fidarestat),
was established indirectly by single-crystal X-ray analysis of (+)-(2S,4S)-8 ... Cited by 29 - Related articles - BL Direct - All 4 versions
N Ashizawa, T Aotsuka - Drugs of the Future, 1998 - journals.prous.com To date, the explanation of involvement of the polyol pathway in the
pathogenesis of diabetic complications includes the osmotic stress hypothesis
(3), myo-inositol (MI) hypothesis (4), the redox potential hypothesis (5), ... Cited by 7 - Related articles - All 3 versions
JS Hothersall, RP Muirhead, CE Taylaur, RH … - Biochemistry international, 1992 - ncbi.nlm.nih.gov The level of NADPH, total glutathione and sorbitol have been measured in a
normal (5mM) and hyperglycaemic (35mM glucose) in vitro rat lens model. In
hyperglycaemic conditions, these intermediates are 50%, 84% and 3628% of ... Cited by 8 - Related articles - All 3 versions
